The Effectiveness Of HRV As A Predictor Of Renal Health And Function In The Absence Of Cardiometabolic Diseases. A Pilot Study

Abstract

RESULTS: Sixty-two young adults (mean age (y):26.6; RET: n=27, Wait-list: n=35, 62.9% female) completed the acute bout at week one; 52 of those young adults (RET: n=25, Wait-list: n=27) completed the acute bout at week eight. Average rating of perceived exertion (6-20) was 14±1, and muscle soreness (1-10) was 4±2. There were no significant three-way interactions for state anxiety (p≥0.51) or worry symptoms (p≥0.16). The magnitude of change in state anxiety at week one (d=-0.26, [-0.81 to 0.29]) and week eight (d=-0.10, [-0.64 to 0.45]) were small and non-significant. The magnitude of change in worry symptoms at week one (d=-0.06, [-0.60 to 0.48]) and week eight (d=0.02, [-0.52 to 0.56]) were small and non-significant. CONCLUSION: Single bouts of RE did not elicit significant reductions in state anxiety or worry symptoms 10 minutes post-RE. RET did not change response to acute RE. Clinicians should encourage chronic, guidelines-based RET for maximum anxiolytic benefits.